Marker Therapeutics Inc (MRKR)

[hanscott]

The Arm A data does seem a bit confusing but if you look at slide 14 it appears to show the Arm A patient's data before and after chemo for the first three months (grey area). Specifically they appear to be measuring the size of a target tumor in the pancreas (Y-axis). With the info we have so far it's not clear if they measured lymph nodes or other metastases which can also be considered in the categorization of pancreatic cancer.

https://www.markertherapeutics.com/wp-content/uploads/2019/07/TACTOPS-Investor-Presentation-FINAL-7-21-19-PDF.pdf

Each seems to show what appears to me as stable disease or partial response between the start and end of the chemo-only period (grey). But to me it looks like Patient's 5 (medium blue), 8 (dark brown), and 9 ("too early to tell") all had slight progression of disease during chemo only so I wonder why they are not in Arm B.

But IIRC anything less than a ~20% change is considered stable disease.

Similarly for Arm B, to me it looks like Patient 2 (brown) had a stable response to chemo but is not in Arm A. . . ???

Hopefully it's all cleared up during the CC and before the market opens.